HK1206719A1 - Solid forms of (s) 2 methoxy 3 4 [2 (5 methyl 2 phenyl oxazol 4 yl) ethoxy] benzo[b]thiophen 7 yl propionic acid and of salts thereof (s) 2 3 4 [2 (5 2 4 ) ] [b] 7 - Google Patents

Solid forms of (s) 2 methoxy 3 4 [2 (5 methyl 2 phenyl oxazol 4 yl) ethoxy] benzo[b]thiophen 7 yl propionic acid and of salts thereof (s) 2 3 4 [2 (5 2 4 ) ] [b] 7

Info

Publication number
HK1206719A1
HK1206719A1 HK15107151.3A HK15107151A HK1206719A1 HK 1206719 A1 HK1206719 A1 HK 1206719A1 HK 15107151 A HK15107151 A HK 15107151A HK 1206719 A1 HK1206719 A1 HK 1206719A1
Authority
HK
Hong Kong
Prior art keywords
thiophen
benzo
ethoxy
methoxy
salts
Prior art date
Application number
HK15107151.3A
Other languages
English (en)
Chinese (zh)
Inventor
盧卡斯‧德雷耶
安德烈‧埃利 é
卡斯藤‧芬里希
奧拉夫‧格羅斯曼
彼得‧莫爾
烏爾斯‧施維特
赫爾穆特‧施塔爾
尼科爾‧維膝巴赫
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1206719A1 publication Critical patent/HK1206719A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15107151.3A 2012-09-12 2015-07-27 Solid forms of (s) 2 methoxy 3 4 [2 (5 methyl 2 phenyl oxazol 4 yl) ethoxy] benzo[b]thiophen 7 yl propionic acid and of salts thereof (s) 2 3 4 [2 (5 2 4 ) ] [b] 7 HK1206719A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12184009 2012-09-12
PCT/EP2013/068561 WO2014040936A1 (en) 2012-09-12 2013-09-09 Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof

Publications (1)

Publication Number Publication Date
HK1206719A1 true HK1206719A1 (en) 2016-01-15

Family

ID=47044773

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107151.3A HK1206719A1 (en) 2012-09-12 2015-07-27 Solid forms of (s) 2 methoxy 3 4 [2 (5 methyl 2 phenyl oxazol 4 yl) ethoxy] benzo[b]thiophen 7 yl propionic acid and of salts thereof (s) 2 3 4 [2 (5 2 4 ) ] [b] 7

Country Status (11)

Country Link
US (2) US20150182505A1 (de)
EP (1) EP2895469B1 (de)
JP (1) JP2015528476A (de)
KR (1) KR20150054829A (de)
CN (1) CN104619689B (de)
BR (1) BR112015005350A2 (de)
CA (1) CA2879500A1 (de)
HK (1) HK1206719A1 (de)
MX (1) MX2015002095A (de)
RU (1) RU2015110641A (de)
WO (1) WO2014040936A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
SI2389166T1 (sl) * 2009-01-23 2013-02-28 F. Hoffmann-La Roche Ag Farmacevtski sestavek, ki obsega aleglitazar
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
ES2552310T3 (es) * 2009-12-07 2015-11-27 F. Hoffmann-La Roche Ag Proceso para la obtención de derivados de ácido propiónico

Also Published As

Publication number Publication date
CA2879500A1 (en) 2014-03-20
MX2015002095A (es) 2015-05-11
JP2015528476A (ja) 2015-09-28
CN104619689A (zh) 2015-05-13
CN104619689B (zh) 2017-08-08
KR20150054829A (ko) 2015-05-20
RU2015110641A (ru) 2016-11-10
BR112015005350A2 (pt) 2017-07-04
EP2895469A1 (de) 2015-07-22
WO2014040936A1 (en) 2014-03-20
US20150182505A1 (en) 2015-07-02
EP2895469B1 (de) 2017-10-18
US20170281602A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CY2018031I2 (el) Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης
IL242279A (en) Converted compounds of 3-chloro-n- [3 - (pyrimidine-2-ylamino) phenyl] propanamide and their salts
IL255030A0 (en) History of n-arylamidine-modified trifluoroethyl sulfide as acaricides and insecticides
PT3412676T (pt) Derivados cíclicos de éster de ácido borónico, método para a sua preparação e suas utilizações terapêuticas
EP2680849A4 (de) 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamid-analoga als mglur5-negative allosterische modulatoren und verfahren zu ihrer herstellung und verwendung
BR112013019509A2 (pt) derivados heterocíclicos
FR2988609B1 (fr) Formulation pour l'hormonotherapie
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
EP2619194A4 (de) Fettsäurederivate aus katechinen und verfahren zu ihrer verwendung
FR2982236B1 (fr) Pylone d'accrochage pour turbomachine
SG10201505619QA (en) Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)­benzofuran-2-ylcarbonylamino]ethoxy}benzamide
HK1191940A1 (en) 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators mglur5 5-(/-)-2-/2--
BR112012020358A2 (pt) metosd de secagem para artigo verde ceramico
CO7010830A2 (es) Derivados de 3-[(1,3-tiazol-4-ilmetoxiimino)(fenil)metil]-2-sustituido-1,2,4-oxadiazol-5(2h)-ona fungicidas
DK2523960T3 (da) Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring
HK1206719A1 (en) Solid forms of (s) 2 methoxy 3 4 [2 (5 methyl 2 phenyl oxazol 4 yl) ethoxy] benzo[b]thiophen 7 yl propionic acid and of salts thereof (s) 2 3 4 [2 (5 2 4 ) ] [b] 7
IL232693B (en) Crystal structures of 2-(2-methylamino-pyrimidin-4-yl)-1h-1indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl] -Amide
CO7010831A2 (es) Derivados de 3-[(piridin-2-ilmetoxiimino)(fenil)metil)]-2-sustituido-1,2,4-oxadiazol-5(2h)-ona fungicidas
PL2513088T3 (pl) Nowe pochodne (heterocyklo-tetrahydro-pirydyno)-(piperazynylo)-1-alkanonu i (heterocyklo-dihydro-pirolidyno)-(piperazynylo)-1-alkanonu i ich zastosowanie jako inhibitorów p75
FI20115927A0 (fi) Liukuelementti mäkien kesäkäyttöä varten
GB201106838D0 (en) Preparation of "normal" model for normalised g & g processing
CO6930371A2 (es) Derivados fungicidas de 3-{fenil[(heterociclilmetoxi)imino]metil}-1,2,4-oxadiazol-5(4h)-ona sustituidos en 4
FI20115230A (fi) Järjestely taakkojen käsittelyssä
TH0701001517A (th) การใช้ประโยชน์อนุพันธ์ของฟีนิล (Phenyl Derivatives) สำหรับปรับ DGAT แอคติวิตี้ (DGAT Activity)
UA22984S (uk) Упаковка для кальмара солоно-сушеного «кольца кальмара»

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210904